DRW Securities’s Xenon Pharmaceuticals XENE Stock Holding History

DRW Securities’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,461	Closed	-$318K	–	1538
2026 Q1	$318K	Buy	+5,461	New	+$252K	﹤0.01%	855
2025 Q4	–	Sell	-9,273	Closed	-$374K	–	1755
2025 Q3	$374K	Buy	+9,273	New	+$327K	0.01%	738
2018 Q2	–	Sell	-30,000	Closed	-$147K	–	175
2018 Q1	$147K	Hold	30,000	–	–	0.01%	134
2017 Q4	$85K	Buy	+30,000	New	+$81.6K	0.01%	437

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

DRW Securities's XENE Position: Q2 2026 in Review

DRW Securities sold out of Xenon Pharmaceuticals (XENE) in Q2 2026, closing a stake of 5,461 shares — an estimated $318K sold.

DRW Securities first reported a position in XENE in Q4 2017 and held it in 4 quarters. The position peaked at $374K in Q3 2025. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

DRW Securities reported no remaining Xenon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
DRW Securities sold 5,461 Xenon Pharmaceuticals shares in Q2 2026, an estimated $318K.
DRW Securities first reported a position in Xenon Pharmaceuticals in Q4 2017 and held it in 4 quarters.
DRW Securities's Xenon Pharmaceuticals position peaked at $374K in Q3 2025.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on DRW Securities's 13F filing for Q2 2026, filed 14 Aug 2026.